Loading...
Patients with moderate-to-severe psoriasis seem to have a greater risk for developing psoriatic arthritis. Therefore, it is not surprising that new agents for either psoriasis or psoriatic arthritis are tested for both conditions.
In this industry-funded, phase III study, investigators randomized 397 adults with active psoriatic arthritis to receive placebo or a human anti-interleukin-17A monoclonal antibody (secukinumab) subcutaneously in doses of 300 mg, 150 mg, and 75 mg weekly for 4 weeks then every 4 weeks.
Results at 24 weeks were as follows:
The proportion of patients achieving ≥20% improvement in American College of Rheumatology response criteria involving joint signs and symptoms (the primary outcome) was significantly greater with al…